IDH1 and acute myeloid leukemia: Among the new approvals, five drugs target known AML vulnerabilities; FLT3 (midostaurin [27], gilteritinib [28]), IDH1 (ivosidenib) [29], IDH2 (enasidenib) [30] and BCL2 (venetoclax) [31].